AstraZeneca (LON:AZN) Rating Reiterated by Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, MarketBeat reports. They currently have a £110 ($144.64) target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential downside of 15.68% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, July 25th. Berenberg Bank reissued a “buy” rating and issued a £150 ($197.24) target price on shares of AstraZeneca in a report on Monday. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, May 28th. Jefferies Financial Group lifted their price target on shares of AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the stock a “hold” rating in a research note on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of £105.53 ($138.77).

AstraZeneca Trading Down 1.1 %

Shares of AZN stock opened at £130.46 ($171.55) on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12-month low of GBX 9,461 ($124.40) and a 12-month high of £133.88 ($176.04). The stock has a market capitalization of £202.21 billion, a P/E ratio of 4,181.41, a P/E/G ratio of 1.08 and a beta of 0.15. The firm’s 50 day moving average is £125.55 and its 200 day moving average is £117.88.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.